Adjuvant docetaxel for node-positive breast cancer [3] (multiple letter)

New England Journal of Medicine

Volumn 353, Issue 9, 2005, Pages 954-955

  Ahluwalia, Manmeet S ^a   Daw, Hamed A ^b   Noronha, Vanita ^c   Martin, Miguel ^d   Vogel, Charles ^e  

^a FAIRVIEW HOSPITAL   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Cancer Research Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ANTINEOPLASTIC AGENT; CAF PROTOCOL; FLUOROURACIL; TAXOID; GRANULOCYTE COLONY STIMULATING FACTOR;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; LETTER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; SEPSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; MORTALITY; NEUTROPENIA; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; NEUTROPENIA; SEPSIS; TAXOIDS; GRANULOCYTE COLONY-STIMULATING FACTOR;

EID: 24044499655     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMc051802     Document Type: Letter

References (0)